NOX-A12: Phase IIa started

Noxxon began an open-label, dose-escalation, European Phase IIa trial to evaluate 1, 2 and 4 mg/kg NOX-A12 in combination with Velcade bortezomib and dexamethasone in 8 cycles of 21 days in about 28 ...